ClinicalTrials.gg
RecruitingNCT06055504Updated Feb 28, 2024

Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)

An interventional study of Control Strategy and Personalized precision ICD implantation Strategy based in genetic findings and CMR results in Non-ischemic Dilated Cardiomyopathy, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Recruiting at 31 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Cardiomyopathy, Dilated with a site in Spain — 6 open to participants now, 9 under way, 3 of them phase 3. Cardiomyopathy, Dilated · Spain.

Planned enrollment
Largest of 13
900 · median 70
Started
2023
the only one that year
No phase
2 of 20
1 open now
Registered
15th of 20
by date
Lead sponsor
1 of 20
Consorcio Centro de Investigación Biomédica en Red (CIBER)

Among the 20 studies in Cardiomyopathy, Dilated with a site in Spain, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 2 with no phase, and was the 15th registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

6 of the 20 studies in Cardiomyopathy, Dilated with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Cardiomyopathy, Dilated with a site in Spain, or all of them as a file.
02

Study summary

Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for Sudden Cardiac Death (SCD) prevention in patients with non-ischemic dilated cardiomyopathy with Left Ventricular Ejection Fraction (LVEF) ≤35%

Read the detailed description

Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for SCD prevention in patients with non-ischemic dilated cardiomyopathy with LVEF≤35%

Randomization will be 1:1 and patients are allocated to either control strategy or intervention strategy.

In the control strategy group, patients will get an Implantable Cardioverter Defibrillator (ICD) implanted. Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a Dilated Cardiomyopathy DCM-causing pathogenic or likely pathogenic genetic variants or Late Gadolinium Enhancement (LGE) in Cardiac Magnetic Resonance (CMR). Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.

03

Conditions studied

  • Non-ischemic Dilated Cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the time of screening.
  • Previously established diagnosis of Non-ischemic DCM
  • Optimised medical treatment at maximum tolerated doses for at least 3 months prior to the screening date.
  • functional class II-III.
  • ≤ 35% documented by CMR as study procedure.
  • greater than 12 months.

Exclusion criteria

Exclusion Criteria:

  • History of coronary artery disease justifying the presence of ventricular dysfunction, defined as: history of coronary revascularisation or presence of significant coronary stenosis (≥50% in left main or ≥70% in a major epicardial artery) on invasive or non-invasive coronary angiography (coronary CT)
  • Left ventricular dysfunction attributed to congenital heart disease, valvular disease, alcohol abuse or chemotherapy.
  • Hypertrophic or infiltrative cardiomyopathy, active myocarditis or constrictive pericarditis.
  • History of recovered sudden death or sustained ventricular tachycardia.
  • functional class IV.
  • Waiting list for cardiac transplantation in emergency 0.
  • Receiver of a solid organ transplant (lung, liver, heart or kidney).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Other
    Control Strategy

    Other: Control Strategy

  • Experimental
    Personalized precision ICD implantation Strategy based in genetic findings and CMR results

    Other: Personalized precision ICD implantation Strategy based in genetic findings and CMR results

Interventions

  • OtherControl Strategy

    ICDs will be implanted in all patients according to current recommendations

  • OtherPersonalized precision ICD implantation Strategy based in genetic findings and CMR results

    Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.

06

What researchers measure

Primary outcomes

  1. Composite end-point of all cause death, hospitalization due to device-related complications, and non-fatal major arrhythmic events.

    Time frame: 4 years

Secondary outcomes

  1. All-cause death

    Time frame: 4 years

  2. SCD

    Time frame: 4 years

  3. Hospitalisation for device-related complications

    Time frame: 4 years

  4. Non-fatal major arrhythmic events

    Time frame: 4 years

  5. cost-effectiveness

    Incremental Cost-effectiveness ratio (ICER) of personalized ICD allocation strategy in non-ischemic DCM \[ Time Frame: The time horizon of the evaluation will be limited to 4 years \] The ICER of the personalized ICD allocation strategy compared with standard strategy is defined as the ratio between the variation in costs and the variation in effectiveness between both strategy groups. In the personalized strategy group, costs will include those related to personalization tests (CMR and genetic analysis) plus costs related to implanting and carrying an ICD (in the number of patients who eventually receive a device). In the control group, costs will include only the latter concept. Costs will be measured in Euros. The variation in effectiveness will be measured both in terms of life years gained, measured in years, and in terms of quality of life gained, measured in QALY. In the first case, ICER will be measured as Euros/year; in the second, it will be measured as Euros/QALY.

    Time frame: 4 years

  6. Quality of life assessed by KCCQ, EQ-5D and HADS

    Time frame: 4 years

07

Study locations

21 of 31 sites recruiting
  • H.C.U de Santiago de Compostela
    Santiago De Compostela, A Coruña 15706, Spain
    Recruiting
    • J. Ramón González-Juanatey · Principal investigator
  • H.U. Central de Asturias
    Oviedo, Asturias 33011, Spain
    Recruiting
    • Rebeca Lorca Gutiérrez · Principal investigator
  • H.U. de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
    Recruiting
    • José González Costello · Principal investigator
  • Hospital Parc Taulí
    Sabadell, Barcelona 08208, Spain
    Not yet recruiting
    • Amadeo Marcelo Rizzo · Principal investigator
  • H.U. A Coruña
    A Coruña, La Coruña 15006, Spain
    Not yet recruiting
    • Maria Generosa Crespo Leiro · Principal investigator
  • H.U. Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
    Recruiting
    • Pablo García Pavía · Principal investigator
  • Hospital General Universitario Dr Balmis
    Alicante, 03010, Spain
    Recruiting
    • Juan Gabriel Martínez · Principal investigator
  • H.U. de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
    Recruiting
    • José M Guerra Ramos · Principal investigator
  • H. Clinic de Barcelona
    Barcelona, 08036, Spain
    Not yet recruiting
    • Josep Lluis Mont Girbau · Principal investigator
  • H.U. Germans Trias i Pujol
    Barcelona, 08916, Spain
    Recruiting
    • Antoni Bayés Genís · Principal investigator
  • H.U. Vall d'Hebron
    Barcelona, Spain
    Recruiting
    • Nuria Rivas Gándara · Principal investigator
  • H.U. Josep Trueta
    Gerona, 17007, Spain
    Recruiting
    • Ramón Brugada Terradellas · Principal investigator
  • H.U. Virgen de las Nieves
    Granada, 18014, Spain
    Not yet recruiting
    • Juan Jiménez Jáimez · Principal investigator
  • Hospital Arnau de Vilanova
    Lérida, 25198, Spain
    Recruiting
    • Jara Gayán Ordás · Principal investigator
  • H.G.U. Gregorio Marañón
    Madrid, 28007, Spain
    Recruiting
    • Javier Bermejo Thomas · Principal investigator
  • H.U. Ramón y Cajal
    Madrid, 28034, Spain
    Not yet recruiting
    • Marta Jiménez-Blanco Bravo · Principal investigator
  • H. Clínico San Carlos
    Madrid, 28040, Spain
    Recruiting
    • Victoria Cañadas Godoy · Principal investigator
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
    Not yet recruiting
    • Borja Ibáñez Cabeza · Principal investigator
  • H.U. 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
    • Fernando Arribas Ynsaurriaga · Principal investigator
  • H.C.U. Virgen de la Arrixaca
    Murcia, 30120, Spain
    Recruiting
    • Domingo Pascual Figal · Principal investigator
  • H.U. Virgen de la Victoria
    Málaga, 29010, Spain
    Recruiting
    • José Manuel García-Pinilla · Principal investigator
  • H.U. Son Llátzer
    Palma De Mallorca, 07198, Spain
    Recruiting
    • Tomás Ripoll Vera · Principal investigator
  • Complejo Hospitalario de Navarra
    Pamplona, 31008, Spain
    Recruiting
    • Maria Teresa Basurte Elorz · Principal investigator
  • H.U de Salamanca
    Salamanca, 37007, Spain
    Recruiting
    • Pedro Luis Sánchez Fernández · Principal investigator
  • H.U. Virgen del Rocio
    Sevilla, 41013, Spain
    Recruiting
    • Eduardo Arana Rueda · Principal investigator
  • Complejo Hospitalario Universitario de Toledo
    Toledo, 45007, Spain
    Not yet recruiting
    • Miguel Ángel Arias Palomares · Principal investigator
  • H.C.U de Valencia
    Valencia, 46010, Spain
    Not yet recruiting
    • Julio Núñez Villota · Principal investigator
  • H.U. Politécnico de la Fe
    Valencia, 46010, Spain
    Recruiting
    • Luis Martínez Dolz · Principal investigator
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
    Not yet recruiting
    • Aurelio Quesada Dorador · Principal investigator
  • H.C.U de Valladolid
    Valladolid, 47003, Spain
    Recruiting
    • José Alberto San Román Calvar · Principal investigator
  • H.U. Miguel Servet
    Zaragoza, 50009, Spain
    Not yet recruiting
    • Maria del Rosario Ortas Nadal · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Oct 2025, 24 months after the start.

Of 28 interventional studies with no phase under Cardiomyopathy, Dilated, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 73. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
Sep 26, 2023
StartActual
Sep 6, 2023
Primary completionEst.
Oct 1, 2025
CompletionEst.
Oct 1, 2027
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06055504
Lead sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Collaborators
Instituto de Salud Carlos III
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Sep 6, 2023
Primary completion
Oct 1, 2025 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Feb 28, 2024

Study contacts

Maria de la Iglesia
Contact
spanish-i@cibercv.es
+34911916749
Projects Department (CIBER)
Contact
proyectos@ciberisciii.es
+34 91 822 28 74
Pablo García Pavía
principal investigator · H.U. Puerta de Hierro, Majadahonda
Antoni Bayés Genís
principal investigator · H.U. Germans Trias i Pujol
Javier Bermejo Thomas
principal investigator · H.G.U. Gregorio Marañón
Javier Díez Martínez
principal investigator · University of Navarra

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion